Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
BACKGROUND
In areas of endemic transmission, malaria in pregnancy is associated with severe maternal anaemia and low-birthweight babies. We studied the efficacy of intermittent treatment doses of sulphadoxine-pyrimethamine in preventing malaria and severe anaemia in pregnancy in a double-blind placebo-controlled trial among primigravid women living in Kilifi District, Kenya.


METHODS
Between January, 1996, and April, 1997, 1264 primigravid women were recruited when they attended for antenatal care, and randomly assigned sulphadoxine-pyrimethamine (640) or placebo (624). Women received one, two, or three doses of study medication depending on the duration of gestation at enrolment. Primary outcome measures were severe anaemia (haemoglobin <8 g/dL) and malaria parasitaemia, assessed at 34 weeks of gestation. Analyses were based on intention to treat among women who had study blood tests at 34 weeks.


RESULTS
30 (5.3%) of 567 women in the sulphadoxine-pyrimethamine group and 199 (35.3%) of 564 in the placebo group had peripheral parasitaemia (protective efficacy 85% [95% CI 78-90], p<0.0001). 82 (14.5%) and 134 (23.7%) had severe anaemia (protective efficacy 39% [22-52], p<0.0001). Even women who booked late and received only one dose of sulphadoxine-pyrimethamine benefited significantly from the intervention. The effects were seen both in women who owned insecticide-treated bednets and in women who did not.


CONCLUSIONS
Intermittent presumptive treatment with sulphadoxine-pyrimethamine is an effective, practicable strategy to decrease the risk of severe anaemia in primigravidae living in malarious areas.
Shulman
C E
CE
London School of Hygiene and Tropical Medicine, UK. c.shulman@lshtm.ac.uk
Dorman
E K
EK
Cutts
F
F
Kawuondo
K
K
Bulmer
J N
JN
Peshu
N
N
Marsh
K
K
D000740:Anemia / Q000209:etiology / Q000517:prevention & control*; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D001512:Bedding and Linens; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019353:Endemic Diseases; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007306:Insecticides; D007630:Kenya; D016778:Malaria, Falciparum / Q000150:complications / Q000517:prevention & control*; D018512:Parasitemia / Q000517:prevention & control; D010298:Parity; D010919:Placebos; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000517:prevention & control*; D011739:Pyrimethamine / Q000008:administration & dosage / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000962:Antimalarials; D004338:Drug Combinations; D006454:Hemoglobins; D007306:Insecticides; D010919:Placebos; D013413:Sulfadoxine; D011739:Pyrimethamine